Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer

Pengfei Xu1, Huan Qu1, Joy C Yang1

  • 1Department of Urologic Surgery, School of Medicine, University of California, Davis, CA 95817, USA.

Cancers
|October 16, 2025
PubMed
Abstract

Insights

Early enzalutamide treatment boosts immune response in prostate cancer, but resistance leads to suppressed immunity and plasticity. Combining enzalutamide with STAT inhibitors may prevent resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Androgen receptor (AR) inhibitors like enzalutamide can drive prostate cancer to neuroendocrine prostate cancer (NEPC).
  • The role of immune signaling in enzalutamide-induced lineage plasticity is not well understood.

Purpose of the Study:

  • To investigate the impact of enzalutamide on immune signaling pathways during prostate cancer progression.
  • To explore the potential of targeting immune pathways to overcome enzalutamide resistance and lineage plasticity.

Main Methods:

  • Transcriptomic analysis of patient samples and cell lines.
  • Assessment of interferon (IFN) and interleukin (IL) signaling pathways (IFNγ, IFNα, IL6-JAK-STAT3).
  • Functional assays evaluating cytokine response and STAT1 inhibition with fludarabine.

Main Results:

  • Immune pathways (IFNγ, IFNα, IL6-JAK-STAT3) were suppressed in NEPC and enzalutamide-resistant cells.
  • Early enzalutamide treatment enhanced IFNγ and IL6 responsiveness and activated JAK/STAT signaling.
  • Early-stage cells showed sensitivity to STAT1 inhibition, which was lost in resistant cells.

Conclusions:

  • Enzalutamide initially enhances immune response but resistance involves immune suppression and plasticity.
  • A therapeutic window exists for combining enzalutamide with STAT inhibitors to prevent resistance and plasticity.